MMP mediated degradation of type VI collagen is highly associated with liver Fibrosis - Identification and validation of a novel biochemical marker assay

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Veidal, Sanne Skovgård ^a,b   Karsdal, Morten Asser ^a   Vassiliadis, Efstathios ^a,b   Nawrocki, Arkadiusz ^b   Larsen, Martin Røssel ^b   Nguyen, Quoc Hai Trieu ^a   Hägglund, Per ^d   Luo, Yunyun ^c   Zheng, Qinlong ^c   Vainer, Ben ^e   Leeming, Diana Julie ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c Nordic Bioscience Beijing   (China)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; COLLAGEN TYPE 6; GELATINASE A; GELATINASE B; MONOCLONAL ANTIBODY; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER FIBROSIS; MASS SPECTROMETRY; NONHUMAN; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; LIVER CIRRHOSIS; MALE; METABOLISM; MOUSE; SPRAGUE DAWLEY RAT; VALIDATION STUDY; WISTAR RAT;

ANIMALIA; RATTUS;

ANIMALS; BIOLOGICAL MARKERS; CARBON TETRACHLORIDE; COLLAGEN TYPE VI; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MASS SPECTROMETRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

EID: 80052830980     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024753     Document Type: Article

References (39)

1. Friedman SL, (2003) Liver fibrosis - from bench to bedside. J Hepatol 38 (Suppl 1): S38-S53.
2. Gressner OA, Weiskirchen R, Gressner AM, (2007) Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 381: 107-113.
3. Bedossa P, Dargere D, Paradis V, (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38: 1449-1457.
4. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, et al. (1986) Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1: 523-525.
5. Veidal SS, Bay-Jensen AC, Tougas G, Karsdal MA, Vainer B, (2010) Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. Dis Markers 28: 15-28.
6. Kumar V, Abbas AK, Fausto N, (2005) Tissue renewal and repair: regeneration, healing, and fibrosis. Pathologic basis of disease Philadelphia, Pennsylvania, USA Elsevier Saunders pp. 87-118.
7. Schuppan D, (1990) Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 10: 1-10.
8. Schuppan D, Ruehl M, Somasundaram R, Hahn EG, (2001) Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21: 351-372.
9. Lochter A, Bissell MJ, (1999) An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS 107: 128-136.
10. Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, et al. (2008) Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 10: R63.
11. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, et al. (2009) Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14: 181-202.
12. Hemmann S, Graf J, Roderfeld M, Roeb E, (2007) Expression of MMPs and TIMPs in liver fibrosis- a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 46: 955-975.
13. Kirimlioglu H, Kirimlioglu V, Yilmaz S, (2008) Expression of matrix metalloproteinases 2 and 9 in donor liver, cirrhotic liver, and acute rejection after human liver transplantation. Transplant Proc 40: 3574-3577.
14. Gelse K, Poschl E, Aigner T, (2003) Collagens-structure, function, and biosynthesis. Adv Drug Deliv Rev 55: 1531-1546.
15. von der MH, Aumailley M, Wick G, Fleischmajer R, Timpl R, (1984) Immunochemistry, genuine size and tissue localization of collagen VI. Eur J Biochem 142: 493-502.
16. Ricard-Blum S, Dublet B, van der Rest M, (2000) Unconventional Collagens Oxford University Press, United States pp. 4-20.
17. Chang J, Nakajima H, Poole CA, (1997) Structural colocalisation of type VI collagen and fibronectin in agarose cultured chondrocytes and isolated chondrons extracted from adult canine tibial cartilage. J Anat 190: 523-532.
18. Kuo HJ, Maslen CL, Keene DR, Glanville RW, (1997) Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen. J Biol Chem 272: 26522-26529.
19. Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R, et al. (1992) Binding of the proteoglycan decorin to collagen type VI. J Biol Chem 267: 5250-5256.
20. Martinez-Hernandez A, Amenta PS, (1993) The hepatic extracellular matrix. I. Components and distribution in normal liver. Virchows Arch A Pathol Anat Histopathol 423: 1-11.
21. Gerling B, Becker M, Staab D, Schuppan D, (1997) Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis. N Engl J Med 336: 1611-1612.
22. Ji X, Li S, Kong X, Xu G, Chen J, et al. (1997) Clinical significance of serum 7S collagen and type VI collagen levels for the diagnosis of hepatic fibrosis. Chin Med J (Engl) 110: 198-201.
23. Shahin M, Schuppan D, Waldherr R, Risteli J, Risteli L, et al. (1992) Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatology 15: 637-644.
24. Stickel F, Urbaschek R, Schuppan D, Poeschl G, Oesterling C, (2001) Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig Dis Sci 46: 2025-2032.
25. Gressner AM, Weiskirchen R, (2006) Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 10: 76-99.
26. Martinez-Hernandez A, Amenta PS, (1993) The hepatic extracellular matrix. II. Ontogenesis, regeneration and cirrhosis. Virchows Arch A Pathol Anat Histopathol 423: 77-84.
27. Schuppan D, Ruhlmann T, Hahn EG, (1985) Radioimmunoassay for human type VI collagen and its application to tissue and body fluids. Anal Biochem 149: 238-247.
28. Weiler-Normann C, Herkel J, Lohse AW, (2007) Mouse models of liver fibrosis. Z Gastroenterol 45: 43-50.
29. Gefter ML, Margulies DH, Scharff MD, (1977) A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet 3: 231-236.
30. Clariá J, Jimenez W, (1999) Renal dysfunction and ascites in carbon tetrachloride-induced cirrhosis in rats. The Liver and the Kidney. pp. 379-396 Blackwell Science, Boston.
31. Munoz-Luque J, Ros J, Fernandez-Varo G, Tugues S, Morales-Ruiz M, et al. (2008) Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 324: 475-483.
32. Botney MD, Kaiser LR, Cooper JD, Mecham RP, Parghi D, et al. (1992) Extracellular matrix protein gene expression in atherosclerotic hypertensive pulmonary arteries. Am J Pathol 140: 357-364.
33. Sondergaard BC, Wulf H, Henriksen K, Schaller S, Oestergaard S, et al. (2006) Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage 14: 759-768.
34. Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M, et al. (2005) Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 37: 425-430.
35. Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, et al. (2005) In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 3: 553-580.
36. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, et al. (2010) A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 43: 899-904.
37. Veidal SS, Vassiliadis E, Barascuk N, Zhang C, Segovia-Silvestre T, et al. (2010) Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int 30: 1293-1304.
38. Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, et al. (2010) Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 3: 5.
39. Mehta G, Rothstein KD, (2009) Health maintenance issues in cirrhosis. Med Clin North Am 93: 901-9ix.